[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356446-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356446-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","from-mechanism-to-clinic-a-panoramic-perspective-on-targeting-hmox1-to-overcome-drug-resistance","From mechanism to clinic - a panoramic perspective on targeting HMOX1 to overcome drug resistance","","Drug resistance is a pivotal factor leading to the failure of cancer therapy, in which heme oxygenase-1 (HMOX1) shows complex and paradoxical roles. HMOX1 protects cancer cells from chemotherapeutic oxidative damage via antioxidant activity, while its downstream product carbon monoxide (CO) suppresses apoptosis and supports acquired resistance. Excessive HMOX1 induction also drives free-iron accumulation, lipid-peroxide buildup, and ferroptosis, creating a strategy to overcome resistance. The review synthesizes HMOX1 inducers, inhibitors, and combination sensitization approaches for translation to clinical practice.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/from-mechanism-to-clinic-a-panoramic-perspective-on-targeting-hmox1-to-overcome-drug-resistance/356446/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/from-mechanism-to-clinic-a-panoramic-perspective-on-targeting-hmox1-to-overcome-drug-resistance/356446.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does HMOX1 contribute to drug resistance in cancer therapy?","Question",{"text":63,"@type":64},"HMOX1 can protect cancer cells from oxidative damage caused by chemotherapeutic drugs through antioxidant properties. Its downstream product carbon monoxide (CO) can inhibit apoptosis, supporting acquired drug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What alternative mechanism allows HMOX1 to help overcome drug resistance?",{"text":68,"@type":64},"Overactivation of HMOX1 increases intracellular free iron, leading to excessive lipid peroxides and ferroptosis. This mechanism may provide a novel opportunity to counter drug resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review focus on for therapeutic targeting of HMOX1?",{"text":72,"@type":64},"It summarizes multiple mechanisms of HMOX1 in drug resistance, emphasizing HMOX1 inducers and inhibitors and synergistic sensitization strategies in combination with other therapies to support clinical translation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356446,1790873044,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Journal of Cancer Research and Clinical Oncology (2026) 152:58  \n[https://doi.org/10.1007/s00432-026-06439-3](https://doi.org/10.1007/s00432-026-06439-3)  \nREVIEW  \nFrom mechanism to clinic: a panoramic perspective on targeting HMOX1 to overcome drug resistance  \nDan Huang1 · Yuxin Ma1 · Wenya Gao1 · Qi Xie1  \nReceived: 21 December 2025 / Accepted: 9 February 2026 © The Author(s) 2026  \nAbstract  \nDrug resistance is a pivotal factor leading to the failure of cancer therapy, within which heme oxygenase-1 (HMOX1) plays a complex and paradoxical dual role. On one hand, HMOX1 protects cancer cells from oxidative damage induced by chemotherapeutic drugs through its antioxidant properties. Concurrently, its catalytic downstream product, carbon monoxide (CO), inhibits cancer cell apoptosis, thereby mediating acquired drug resistance. On the other hand, HMOX1 is a key source of intracellular free iron. When its activity is excessively induced, it leads to the accumulation of excessive free iron, triggering the buildup of lipid peroxides and ferroptosis, which presents a novel opportunity to overcome drug resistance. This demonstrates that the function of HMOX1 can switch depending on its degree of activation. Therefore, a thorough analysis of its regulatory network and the mechanisms of its functional switch within different microenvironments is crucial for developing novel therapeutic strategies that target HMOX1 to overcome drug resistance. This review systematically summarizes the multiple mechanisms of HMOX1 in drug resistance, with a focus on HMOX1 inducersand inhibitors, as well as synergistic sensitization strategies in combination with other therapies. It aims to provide a comprehensive theoretical foundation and a forward-looking perspective for translating HMOX1-targeted therapy from basic research to clinical practice.  \nKeywords HMOX1 · Drug resistance · Antioxidant stress · Ferroptosis · Future perspectives  \nIntroduction  \nMalignant tumors represent a major public health threat to humanity. In 2022, there were approximately 19.7 million new cancer cases and 9.7 million cancer-related deaths worldwide (Bray et al. 2024) . Despite breakthroughs in chemotherapy, targeted therapy, and immunotherapy that have significantly improved patient survival, drug resistance remains the primary cause of disease progression,  \nDan Huang and Yuxin Ma contributed equally to this work.  \n􀀍 Wenya Gao [gaowenya522@163.com](gaowenya522@163.com)  \nDan Huang  \n[danhuang_cacms@163.com](danhuang_cacms@163.com)  \nYuxin Ma  \n[mayuuxin@163.com](mayuuxin@163.com)  \n1 Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China  \nrecurrence, and ultimate treatment failure (Vasan et al. 2019) .  \nChemotherapy, a cornerstone of cancer treatment, utilizes one or more anticancer agents in standardized regimens. Its major limitations, however, are the lack of selectivity of cytotoxic drugs between tumor and normal cells, and the development of resistance to specific or multiple drugs by tumor cells (Engle and Kumar 2022) . Although renowned for its precision, targeted therapy is invariably followed by acquired resistance, often via mechanisms such as target gene mutations (Aldea et al. 2021; Song et al. 2025) . Similarly, immunotherapies, including immune checkpoint inhibitors (ICIs), despite their remarkable efficacy in certain cancers, are constrained by primary or acquired resistance (Pang et al. 2023; Vesely et al. 2022) . The emergence of drug resistance not only severely compromises therapeutic efficacy but also exacerbates the physical and financial burdens on patients.  \nThe mechanisms underlying drug resistance are complex and multifaceted, primarily encompassing the following aspects. (1) Enhanced Drug Efflux: Tumor cells overexpress  \n1 3  \nATP-binding cassette (ABC) transporter family proteins, such as P-glycoprotein, on their surface. These proteins actively pump drugs out of the cell, thereby reducing intracellular drug","cbCaidLl5RXxTdqz","https://ap.wps.com/l/cbCaidLl5RXxTdqz","pdf",1309988,14,"English","# Abstract\n# Introduction","[{\"question\":\"How does HMOX1 contribute to drug resistance in cancer therapy?\",\"answer\":\"HMOX1 can protect cancer cells from oxidative damage caused by chemotherapeutic drugs through antioxidant properties. Its downstream product carbon monoxide (CO) can inhibit apoptosis, supporting acquired drug resistance.\"},{\"question\":\"What alternative mechanism allows HMOX1 to help overcome drug resistance?\",\"answer\":\"Overactivation of HMOX1 increases intracellular free iron, leading to excessive lipid peroxides and ferroptosis. This mechanism may provide a novel opportunity to counter drug resistance.\"},{\"question\":\"What does the review focus on for therapeutic targeting of HMOX1?\",\"answer\":\"It summarizes multiple mechanisms of HMOX1 in drug resistance, emphasizing HMOX1 inducers and inhibitors and synergistic sensitization strategies in combination with other therapies to support clinical translation.\"}]","From mechanism to clinic - a panoramic perspective on targeting HMOX1 to overcome drug resistance | PDF",1790125356,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ef522ee6deda29f35cf669e555178a3.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b3239261b757394ef0b59a18c355bf7.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f41dc6b6ba5509b8189c0e3ca39d409.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b143c8012f65e50e1162351ca1bf5a88.webp",980,1301]